The adviser employs a "passive management" investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
Frequently asked questions
What is the Kelly CRISPR & Gene Editing Technology ETF (XDNA) expense ratio?
The Kelly CRISPR & Gene Editing Technology ETF funds expense ratio is 0.78%.
What is Kelly CRISPR & Gene Editing Technology ETF (XDNA) current stock price?
As of the latest data, Kelly CRISPR & Gene Editing Technology ETF stock price is $7.38, with a previous close of $7.50. Kelly CRISPR & Gene Editing Technology ETF lost -$0.12 in the last trading session, representing a -1.6% loss.
Does Kelly CRISPR & Gene Editing Technology ETF (XDNA) pay dividends?
No. Kelly CRISPR & Gene Editing Technology ETF does not pay a dividend.
